Abstract
In the article “Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy” by Mullin et al.,1 first published online January 13, 2020, the last sentence of the abstract's Results should read “While using rimegepant alone or together with erenumab, patients reported no related adverse events.” The sentence appears correctly in the May 19, 2020, issue. The authors regret the error.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.